药物活性分子

AMG-208是c-Met抑制剂,IC50为9.3 nM。

信号通路 >> 蛋白酪氨酸激酶 >> c-Met的/HGFR

研究领域 >> 癌症

[1]. Albrecht BK, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008, 51(10), 2879-2882.

[2]. Boezio AA, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 2009, 19(22), 6307-6312.

[3]. Liu X, et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010,16(1), 37-45.

苯扎米特 | Foretinib | PHA-665752 | BMS 777607 | 益智二肽 | 沃利替尼 | (3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮 | 特泊替尼 | 美乐替尼 | 6-[[6-(1-甲基-1H-吡唑-4-基)-1,2,4-噻唑并[4,3-b]吡嗪-3-基]硫代]喹啉 | N-[2,5-二氟-4-[[2-(1-甲基-1H-吡唑-4-基)-4-吡啶基]氧基]苯基]-N'-苯基-1,1-环丙烷二甲酰胺 | N-(3-氯苯基)-N-甲基-3-[[3,5-二甲基-4-[(4-甲基哌嗪-1-基)羰基-1H-吡咯-2-基]亚甲基]-2-氧代-2,3-二氢-1H-吲哚-5-磺酰胺 | 恩沙替尼(X-376) | CEP-40783 | 6-[二氟[6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-b]哒嗪-3-基]甲基]喹啉